McPherson, KS, United States of America

Richard L Watson

This inventor holds 48 USPTO granted patents and 16 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Biomedical Innovations. Top assignees: Revalesio Corporation, Kci Licensing, Inc., Maternus Partners, Ltd.. Active years: 1997-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard L Watson. Retrieved from https://idiyas.com/inventor/richard-l-watson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 48 

% Patents Active = 45.8

 

 

Average Co-Inventor Count = 1.9

ph-index = 16

Forward Citations = 1,347(Granted Patents)


Location History:

  • Ruston, WA (US) (2015 - 2016)
  • McPherson, KS (US) (1997 - 2018)

Company Filing History:


Years Active: 1997-2018

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Inflammation Treatment
Diabetes Management
Wound Care
Nanobubbles
Electrokinetic Fluids
Therapeutic Treatment
Mixing Devices
Umbilical Cord Clamp
Fetal ECG
Recovery Enhancement
Digestive Disorders
48 patents (USPTO):Explore Patents

Title: Richard L. Watson: Innovator in Electrokinetic Fluids and Therapeutic Compositions

Introduction: Richard L. Watson, based in McPherson, Kansas, is an accomplished inventor with an impressive portfolio of 48 patents. His innovative work primarily focuses on electrokinetic fluids and their applications in treating various inflammatory conditions. Watson's contributions to the field have the potential to transform therapeutic approaches, making significant strides in biomedical research.

Latest Patents: Among Watson's most recent patents are two remarkable innovations concerning compositions and methods for treating inflammation and multiple sclerosis. His patent on “Compositions and methods for treating inflammation” features electrokinetically-altered fluids that include gas-enriched electrokinetic fluids. These fluids consist of charge-stabilized oxygen-containing nanostructures, which enhance cellular membrane potential and conductivity. This advancement allows for therapeutic applications that modulate intracellular signal transduction linked to inflammatory responses.

The second patent, focusing on “Compositions and methods for treating multiple sclerosis,” similarly utilizes electrokinetically-altered fluids to address neurodegenerative conditions. Watson's compositions aim to regulate cellular membranes and associated proteins, thus providing potential treatments for inflammatory symptoms associated with multiple sclerosis. Both patents highlight various routes of administration and formulations for these electrokinetically-generated solutions.

Career Highlights: Throughout his career, Richard L. Watson has demonstrated a strong commitment to innovation in the medical field. His work at Revalesio Corporation has propelled significant advancements in therapeutic methods, particularly concerning inflammation and neurodegenerative diseases. Watson's extensive patent portfolio showcases his dedication to researching and developing pioneering solutions in these areas.

Collaborations: Watson has collaborated with notable individuals in the industry, including Anthony B. Wood and Gregory J. Archambeau. These partnerships have contributed to enriching the research and application of his innovative ideas and therapeutic compositions.

Conclusion: Richard L. Watson stands out as a leading inventor in the realm of electrokinetic fluids, with a noteworthy track record of patents that address critical medical challenges. His innovative approaches and collaborative efforts continue to inspire advancements in treatments for inflammation and multiple sclerosis, underlining his valuable contributions to biomedical research and innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…